Sp1194
WHAT FACTORS DO PAYORS CONSIDER WHEN DECIDING TO COVER NEW TECHNOLOGY?
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
This session will provide attendees with the knowledge and skills to successfully create and implement new technology into their practices through negotiation with payors and securing support from hospital systems. Learn from experts in reimbursement and insurance negotiation, hear from payors what makes a persuasive case to cover new technology and apply the concepts from this seminar to create a business plan for successful adoption of third space endoscopy.
This session will provide attendees with the knowledge and skills to successfully create and implement new technology into their practices through negotiation with payors and securing support from hospital systems. Learn from experts in reimbursement and insurance negotiation, hear from payors what makes a persuasive case to cover new technology and apply the concepts from this seminar to create a business plan for successful adoption of third space endoscopy.
Presenter
Tracks
Related Products
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
